News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • EyePoint's Phase 3 program for DURAVYU targets durability and safety outcomes.
  • DURAVYU has received three consecutive positive DSMC recommendations.
  • EyePoint appointed a seasoned ophthalmology commercial chief to lead commercialization efforts.
  • EyePoint reports cash runway extending into Q4 2027.
  • Analyst recommends a long trade with $14 entry, $20 target, and $10 stop.
  • Investment horizon specified at 180 trading days.

Latest Articles

NN, Inc. Executive Management to Attend Data Center World 2026

NN, Inc. Executive Management to Attend Data Center World 2026

NN, Inc. announced its executive management team's attendance at Data Center World 2026 to foster industry relationships and deepen understanding of next-generation technologies. The company is capitalizing on a growing electric grid and data center market, recently securing new contracts with AI infrastructure and data center equipment leaders. NN…

Agios Shares Plunge After Novo Nordisk Reports Positive Sickle Cell Results

Agios Shares Plunge After Novo Nordisk Reports Positive Sickle Cell Results

Agios Pharmaceuticals stock dropped 25% after Novo Nordisk announced positive trial results for its experimental sickle cell therapy etavopivat. Novo reported a 27% reduction in vaso-occlusive crisis events and roughly a four-month delay to the first such event versus standard of care. Agios is pursuing an accelerated approval path with the FDA for…

Supreme Court Lets $12 Billion Municipal Bond Class Action Move Forward

Supreme Court Lets $12 Billion Municipal Bond Class Action Move Forward

The U.S. Supreme Court refused to hear an appeal from Bank of America and seven other major banks challenging a lower court's decision to certify a $12 billion class action by U.S. cities. The suit, brought by municipalities including Baltimore, Philadelphia and San Diego, alleges the banks colluded from 2008 to 2016 to inflate rates on thousands o…

ASML: The Cornerstone of AI Chip Supply — Tactical Long Trade

ASML: The Cornerstone of AI Chip Supply — Tactical Long Trade

ASML reported strong Q1 results and raised full-year guidance, confirming its unique position as the supplier of advanced EUV lithography for AI chips. With a market cap near $576B, healthy margins, and active buybacks, the stock is a core way to play AI infrastructure. This trade idea lays out an entry, stop and target for a mid-term swing while f…

Goldman Calls Wall Street's Apple Pessimism Overstated Ahead of Q2 Results

Goldman Calls Wall Street's Apple Pessimism Overstated Ahead of Q2 Results

Goldman Sachs pushed back on negative market sentiment toward Apple ahead of the company's fiscal second-quarter results, arguing that recent share weakness overstates the risks. The bank models EPS of $2.00, above the Street consensus of $1.93, and expects outperformance in iPhone and Mac revenue, gross margins and Services growth. Goldman also hi…

GlobalFoundries Jumps After UMC Signals Wafer Price Increase

GlobalFoundries Jumps After UMC Signals Wafer Price Increase

GlobalFoundries shares climbed 8% on Monday after reports that United Microelectronics Corp. (UMC) plans to raise wafer prices in the second half of the year. UMC told customers the move reflects an evolving supply-demand balance and continued investment needs, while Morgan Stanley upgraded UMC and now models multi-year price increases tied to impr…

Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations

Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations

AnaptysBio has completed the spin-off of its biopharma operations into First Tracks Biotherapeutics and will now operate as a royalty management company. The new virtual model focuses on managing financial collaborations related to Jemperli with GSK and imsidolimab with Vanda, aiming for high operational efficiency and returning value to shareholde…

Intelligent Bio Solutions Initiates Validation Study for Rapid Drug Screening Cartridge Targeting 70% Faster Results

Intelligent Bio Solutions Initiates Validation Study for Rapid Drug Screening Cartridge Targeting 70% Faster Results

Intelligent Bio Solutions Inc. (Nasdaq: INBS) has initiated a validation study to reduce the analysis time of its Intelligent Fingerprinting Drug Screening System from ten minutes to under three minutes. This improvement aims to enhance its competitive position in the growing U.S. roadside drug testing market, projected to reach $1.62 billion by 20…

Widespread Flight Suspensions Persist as Middle Eastern Hubs Remain Closed

Widespread Flight Suspensions Persist as Middle Eastern Hubs Remain Closed

Global air travel continues to face major disruption after the Iran war prompted the closure of key Middle Eastern hubs, including Dubai, Doha and Abu Dhabi. Dozens of airlines have suspended or cancelled services to cities across the region and beyond, with disruption timelines stretching into May, June, July and in some cases October. Carriers ha…

European Gas Edges Up as Mideast Ceasefire Talks Remain Uncertain

European Gas Edges Up as Mideast Ceasefire Talks Remain Uncertain

European natural gas prices ticked higher on Monday after reversing some losses recorded at the end of last week, while investors assessed uncertainty about whether a temporary U.S.-Iran ceasefire and planned talks will hold. Shipping tensions, a disputed ceasefire, and attacks on regional energy infrastructure continue to pressure supplies to Euro…

KUSTOM ENTERTAINMENT, INC. ANNOUNCES PLANNED ADDITION OF FOURTH CONCERT DAY IN THE SECOND QUARTER OF 2026

KUSTOM ENTERTAINMENT, INC. ANNOUNCES PLANNED ADDITION OF FOURTH CONCERT DAY IN THE SECOND QUARTER OF 2026

Kustom Entertainment, a Nasdaq-listed live music event producer, announced it will add a fourth concert day in the second quarter of 2026 to capitalize on increased tourism and regional activity during major global sports events in Kansas City. This expansion aligns with the company's shift to focus solely on entertainment following divestitures of…

GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness

GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness

GH Research PLC welcomes the White House Executive Order aimed at speeding up the development and patient access to innovative therapies for serious mental illnesses, including psychedelic treatments. The company is advancing its proprietary inhaled mebufotenin candidate, GH001, toward a global pivotal Phase 3 trial for treatment-resistant depressi…

Wearable Devices Announces Collaboration with Meta-Bounds to Enable Intuitive Neural Control for AR Glasses

Wearable Devices Announces Collaboration with Meta-Bounds to Enable Intuitive Neural Control for AR Glasses

Wearable Devices Ltd. announced a strategic collaboration with Meta-Bounds Inc. to integrate its AI-powered neural wristband technology with Meta-Bounds' augmented reality hardware. The partnership plans to showcase initial demos at the Augmented World Expo 2026 and aims to develop both short-term intuitive spatial interaction tech and long-term en…

Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

Oragenics, Inc. has initiated dosing of patients in its Phase IIa clinical trial for ONP-002, targeting mild traumatic brain injury (concussion). The trial is underway in Australia, with plans for U.S. trials pending FDA approval. ONP-002 uses a proprietary intranasal delivery system to address neurological injury mechanisms rather than merely symp…